Evoke Pharma Operating Income 2012-2025 | EVOK

Evoke Pharma operating income from 2012 to 2025. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Evoke Pharma Annual Operating Income
(Millions of US $)
2024 $-5
2023 $-7
2022 $-8
2021 $-8
2020 $-13
2019 $-7
2018 $-8
2017 $-11
2016 $-11
2015 $-12
2014 $-13
2013 $-3
2012 $-2
2011 $-2
Evoke Pharma Quarterly Operating Income
(Millions of US $)
2025-03-31 $-1
2024-12-31 $-1
2024-09-30 $-1
2024-06-30 $-1
2024-03-31 $-2
2023-12-31 $-2
2023-09-30 $-2
2023-06-30 $-2
2023-03-31 $-2
2022-12-31 $-2
2022-09-30 $-2
2022-06-30 $-2
2022-03-31 $-2
2021-12-31 $-2
2021-09-30 $-2
2021-06-30 $-2
2021-03-31 $-3
2020-12-31 $-2
2020-09-30 $-2
2020-06-30 $-7
2020-03-31 $-2
2019-12-31 $-1
2019-09-30 $-2
2019-06-30 $-2
2019-03-31 $-2
2018-12-31 $-2
2018-09-30 $-2
2018-06-30 $-2
2018-03-31 $-2
2017-12-31 $-3
2017-09-30 $-4
2017-06-30 $-3
2017-03-31 $-2
2016-12-31 $-2
2016-09-30 $-2
2016-06-30 $-3
2016-03-31 $-3
2015-12-31 $-3
2015-09-30 $-3
2015-06-30 $-3
2015-03-31 $-3
2014-12-31 $-3
2014-09-30 $-4
2014-06-30 $-3
2014-03-31 $-3
2013-12-31 $-2
2013-09-30 $0
2013-06-30 $0
2013-03-31 $0
2012-12-31
2012-09-30 $0
2012-06-30
2011-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.006B $0.010B
Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $20.080B 7.26
Dr Reddy's Laboratories (RDY) India $12.313B 22.35
BridgeBio Pharma (BBIO) United States $6.285B 0.00
Supernus Pharmaceuticals (SUPN) United States $1.825B 14.82
Bausch Health Cos (BHC) Canada $1.673B 1.22
Amphastar Pharmaceuticals (AMPH) United States $1.213B 8.08
Taysha Gene Therapies (TSHA) United States $0.559B 0.00
Personalis (PSNL) United States $0.414B 0.00
Assembly Biosciences (ASMB) United States $0.108B 0.00
Sol-Gel Technologies (SLGL) Israel $0.021B 0.00
Teligent (TLGT) United States $0.000B 0.00